|
TargetMol
myk 461 Myk 461, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/myk+461/Mavacamten/pmc12748787-345-16-19 Average 93 stars, based on 1 article reviews
myk 461 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Selleck Chemicals
mavacampten myk 461 Mavacampten Myk 461, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/myk+461/Mavacamten/bio_rxiv__2025__08__23__671924-210-6-7 Average 93 stars, based on 1 article reviews
mavacampten myk 461 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
MyoKardia
mavacamten (myk-461) Mavacamten (Myk 461), supplied by MyoKardia, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/myk+461/myk+461/pm39836055-151-117-107 Average 90 stars, based on 1 article reviews
mavacamten (myk-461) - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
MedChemExpress
myk 461 Myk 461, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/myk+461/Mavacamten/pm39754660-53-0-6 Average 95 stars, based on 1 article reviews
myk 461 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
MyoKardia
myk‐461, which later became mavacamten Myk‐461, Which Later Became Mavacamten, supplied by MyoKardia, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/myk+461/myk+461/pm39659164-202-36-6 Average 90 stars, based on 1 article reviews
myk‐461, which later became mavacamten - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
MedChemExpress
myk ![]() Myk, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/myk+461/Mavacamten/pmc11218625-165-0-4 Average 95 stars, based on 1 article reviews
myk - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Cayman Chemical
myk-461 ![]() Myk 461, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/myk+461/myk+461/bio_rxiv__2024__05__14__594252-465-5-6 Average 90 stars, based on 1 article reviews
myk-461 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Journal: Journal of molecular and cellular cardiology plus
Article Title: Roles of cMyBP-C phosphorylation on cardiac contractile dysfunction in db/db mice
doi: 10.1016/j.jmccpl.2024.100075
Figure Lengend Snippet: Increased maximal pCa-force on skinned papillary muscle fibers of db/db mice. (A) Experimental plans for measuring papillary muscle contractility in vitro . (B–C) pCa-force relationship and maximal force at pCa 5.5 with (+) and without (−) Mavacamten in WT controls and db/db mice at six months of age. The (−) MYK-461 group was treated with an equal volume of the vehicle, DMSO. (D–E) pCa-force relationship and (F–G) k tr values across WT and db/db fibers in the presence and absence of MYK-461. ns P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and **** P ≤ 0.0001 db/db vs . WT. Data are expressed as mean ± SD (n = 8 fibers/3 hearts), and statistical analyses were performed in all groups by ordinary one-way ANOVA, followed by Tukey’s multiple comparison test with single pooled variance.
Article Snippet:
Techniques: In Vitro, Comparison
Journal: Journal of molecular and cellular cardiology plus
Article Title: Roles of cMyBP-C phosphorylation on cardiac contractile dysfunction in db/db mice
doi: 10.1016/j.jmccpl.2024.100075
Figure Lengend Snippet: Mavacamten improves contractility in isolated cardiomyocytes in vitro . As a proof-of-concept, we used freshly isolated cardiomyocytes from wild-type (WT) and db/db mice (6 months of age, mixed sex) and measured contractility in the presence of mavacamten (MYK-461) at a concentration of 250 nM (A). Fractional shortening (FS%, B), contraction velocity (C), and time to 90 % relaxation (D) were significantly increased in db/db isolated cardiomyocytes, but significantly decreased in cardiomyocytes of db/db mice, compared to untreated and control groups, after administration of MYK-461. (E) Relaxation time constant (t) of calcium transient and (F) Calcium amplitude indicated by peak (340/380) in the absence and presence of MYK-461 were not different between the groups. Two-way ANOVA followed by Tukey’s post hoc test was used; data points were pooled from three independent experiments. Data are expressed as mean ± SE, n = 29 myocytes/3 mice/group. *P ≤ 0.05, ***P ≤ 0.001 and ****P ≤ 0.0001 db/db vs . WT.
Article Snippet:
Techniques: Isolation, In Vitro, Concentration Assay, Control
Journal: bioRxiv
Article Title: Deconvolution of polygenic risk score in single cells unravels cellular and molecular heterogeneity of complex human diseases
doi: 10.1101/2024.05.14.594252
Figure Lengend Snippet: a , Motif enrichment within HCM-CREs identified in two HCM-relevant cell types including cardiomyocyte and pericyte. Motif enrichment was measured by AUC. Row-wise standardization was performed. Only significant enrichment (adjusted P < 0.1, Bonferroni correction) is colored. CDM, cardiomyocyte; Peri, pericyte; AUC, the area under the receiver operating characteristic (ROC) curve. b , Bar plot of gene ontology (GO) enrichment for cardiomyocyte HCM risk genes. Significant GO terms (adjusted P < 0.1, BH correction) with odds ratio greater than five are shown. c , The network module M16 enriched with pericyte HCM risk genes. P -value by hypergeometric test. Edges between module genes are shown. d , Lollipop chart of GO enrichment (biological process) for M16 genes. Significant GO terms (adjusted P < 0.1, BH correction) are shown. e , Schematic of iPSC RNA-seq experiments. iPSC, induced pluripotent stem cell; Myk, Mavacamten; Omec, Omecamtiv mecarbil. f , Expression fold change comparison between HCM risk genes and the background transcriptome in cardiomyocytes across different conditions. The box plot center line, limits, and whiskers represent the median, quartiles, and 1.5x interquartile range (IQR), respectively. P -value by two-sided t -test. NS, not significant; stat, statistics. g , Expression fold change comparison between HCM risk genes and the background transcriptome in HCM-relevant cell types based on an HCM snRNA-seq study. P -value by two-sided t -test. h , Illustration of the genetic regulation of rs886125 in cardiomyocytes. Bar plot: “*” indicates scVINet-heart score percentage greater than 85%. Gene plot: differentially expressed target gene was mapped (in red). Bkg, background; Coaccess, coaccessibility. i , The uniform manifold approximation and projection (UMAP) plot of the left ventricle snRNA-seq dataset showing the expression of ZNF382 in individual cells. Expression was estimated by normalized gene count. Cardiomyocytes are highlighted in the dashed closed curve.
Article Snippet: Cells were treated with 250nM
Techniques: RNA Sequencing Assay, Expressing, Comparison
Journal: bioRxiv
Article Title: Deconvolution of polygenic risk score in single cells unravels cellular and molecular heterogeneity of complex human diseases
doi: 10.1101/2024.05.14.594252
Figure Lengend Snippet: a , Lollipop chart of gene ontology (GO) enrichment (molecular function) for M16 genes. Significant GO terms (adjusted P < 0.1 by Benjamini-Hochberg (BH) correction) are shown. b , Expression fold change comparison between HCM pericyte genes and background transcriptome based on the HCM iPSC RNA-seq data. P -value by two-sided t -test. The box plot center line, limits, and whiskers represent the median, quartiles, and 1.5x interquartile range (IQR), respectively. CDM, cardiomyocyte; Myk, Mavacamten; Omec, Omecamtiv mecarbil; iPSC, induced pluripotent stem cell; NS, not significant. c , Expression analysis of HCM cardiomyocyte and pericyte genes based on the pericyte and cardiomyocyte transcriptome data, respectively. Peri, pericyte. d , The receiver operating characteristic curve (ROC; top) and the precision-recall curve (PRC; bottom) showing scVINet-heart test performance across various cell types in the human left ventricle. The red line and gray area represent the mean and 95% CI, respectively. The dashed gray line indicates the random prediction. AUC, the area under the curve; CI, confidence interval. e , Comparison of scVINet-heart prediction scores between eQTLs and other variants across different tissues and cell types. Comparison was performed using two-sided t -test. ×, adjusted P > 0.1 by BH correction. Rows were standardized. Mesothl, mesothelial cell; Adipo, adipose cell; CDM, cardiomyocyte; Fibro, fibroblast; LEC, lymphatic endothelial cell; Peri, pericyte; Schw, Schwann cell; SmMus, smooth muscle cell; VEC, vascular endothelial cell. f , Enrichment of transcription factor binding site (TFBS) disrupting variants within scVINet-heart-prioritized variants (various thresholds applied). Enrichment was quantified by t -statistics. ×, adjusted P > 0.1 by BH correction. g , Enrichment of scVINet-heart-prioritized HCM-associated variants within HCM-CREs. OR, odds ratio. OR and CI by two-sided Fisher’s exact test. OR is annotated by the solid line and 95% CI is represented by the shaded area. h-i , Summary statistics of prioritized HCM risk variants in cardiomyocytes ( h ) and pericytes ( i ) using different annotations.
Article Snippet: Cells were treated with 250nM
Techniques: Expressing, Comparison, RNA Sequencing Assay, Binding Assay